Release Date: November 07, 2024
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: Can you provide insight into when the RCC expansion cohort might be completed and when a pivotal trial for potential approval could start? Also, how do the 316 data read through to the 329 autoimmune program? A: We aim to enroll approximately 20 patients in the expansion cohort to ascertain response rate and durability, with a program update expected next year. Regarding the 329 program, we are encouraged by the dagger effect seen in the 316 program and have confidence that this will carry forward into the 329 program. We plan to use chemotherapy alone in the autoimmune setting and will pressure test the ability to reduce or eliminate lymphodepletion as a key objective in the early phase of the study. - Dr. Zachary Roberts, EVP of R&D, CMO
Q: Could you give us a better sense of the grade five events reported in the data today? Were there any confounding effects that led to those cases? A: In oncology, especially with advanced metastatic disease, adverse events are often confounded by the underlying disease and the doses used in phase one trials. Each case of adverse events, including grade five events, is complex and confounded. - Dr. David Chang, CEO
Q: How are you seeing the screening rate for MRD positivity in your first-line lymphoma study, and how is the pace of enrollment? A: The enthusiasm and engagement from clinical trial sites have been high. The trial is progressing as planned, with community sites showing significant activity. The screening process is providing prognostic benefits to patients, even those who screen MRD negative. - Dr. Zachary Roberts, EVP of R&D, CMO
Q: Can you discuss the safety profile of ALLO-316, particularly in relation to the grade five adverse events and how this might translate into your autoimmune program? A: The safety findings are being carefully evaluated. The grade five events are confounded by the advanced disease state of patients. The dagger technology enhances the pharmacodynamic effect of CAR T, and we are focused on finding the right balance of cell dose and lymphodepletion. - Dr. David Chang, CEO
Q: What kind of durability do you need to see in ALLO-316 to meet with the FDA on a pivotal design? What indications are you expecting to pursue with ALLO-329? A: We have ongoing remissions at four and six months in patients treated with the phase one B regimen. The FDA's RMAT designation allows for more frequent discussions, and we await further durability data. For ALLO-329, we are focusing on rheumatologic conditions, with lupus being a primary area of interest. - Dr. Zachary Roberts, EVP of R&D, CMO
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.